UnknownNot Applicable

Irisin Expression and Gene Polymorphism With Peripartum Cardiomyopathy.

Egypt45 participantsStarted 2021-02-20

Plain-language summary

this is an observertional study aimed at Study the association between the level of irisin expression and (Fibronectin Type III Domain Containing 5 (FDNC5) gene polymorphism in female patients with peripartum cardiomyopathy.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * This study will include females aged between 18 and 45 years old who have been diagnosed and treated clinically for peripartum cardiomyopathy Exclusion Criteria: * Age less than 18 or more than 45 year old * females with dilated cardiomyopathy due to other etiology or outside the time frame of occurrence of peripartum cardiomyopathy

What they're measuring

Irisin level

Timeframe: 4 months

FNDC5 Genotyping

Timeframe: 4 months

Trial details

NCT IDNCT04927715

SponsorSohag University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-01-30

Contact for this trial

Ali mo Altaher, lecturer

01003376529 dr.ali.altaher30@gmail.com

View on ClinicalTrials.gov More Peripartum Cardiomyopathy trials